BS_M1PVEHCM
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 19.87516425755585
- age_years
- 16.677
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.363
- KRAS_SIGNALING_DN+0.328
- SPERMATOGENESIS+0.255
- HEDGEHOG_SIGNALING+0.237
- MYOGENESIS+0.146
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.146
- OXIDATIVE_PHOSPHORYLATION+0.112
- UV_RESPONSE_UP+0.096
- APICAL_SURFACE+0.084
- HEME_METABOLISM+0.069
Top 10 suppressed
- E2F_TARGETS-0.589
- G2M_CHECKPOINT-0.520
- MYC_TARGETS_V1-0.479
- ALLOGRAFT_REJECTION-0.456
- INTERFERON_GAMMA_RESPONSE-0.455
- DNA_REPAIR-0.445
- INTERFERON_ALPHA_RESPONSE-0.439
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.435
- IL6_JAK_STAT3_SIGNALING-0.428
- MYC_TARGETS_V2-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_WCRKYV0T | low-grade glioma | — | 0.967 |
| 2 | BS_TG93XC55 | Ganglioglioma | — | 0.967 |
| 3 | BS_AJ6X83G5 | DNET | — | 0.961 |
| 4 | SRR1324371 | GTEX | — | 0.944 |
| 5 | MNG1089 | — | — | 0.942 |
| 6 | SRR1439873 | GTEX | — | 0.942 |
| 7 | SRR1434526 | GTEX | — | 0.940 |
| 8 | SRR1348159 | GTEX | — | 0.940 |
| 9 | SRR1334564 | GTEX | — | 0.939 |
| 10 | MNG1015 | — | — | 0.938 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.363 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.328 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.255 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.237 | Inavolisib | — uncovered |
| MYOGENESIS | 0.146 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.146 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.112 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.096 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.084 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.069 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.024 | Inavolisib | — uncovered |